Sequenom Inc. entered into a clinical research collaboration with the University of California, San Diego Moores Cancer Center to explore the utility of Sequenom’s new liquid biopsy assay to comprehensively profile circulating cell-free tumor DNA in blood to enable serial monitoring and assist with therapy selection in cancer patients.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
